Moderna’s Pain Continues Amid Flurry Of Downgrades Following ‘Tough’ R&D Day
Investor's Business DailyModerna stock tumbled again Friday on a series of downgrades and price-target cuts following a “tough update” at its R&D Day.
The post Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day appeared first …